Last reviewed · How we verify
Switch to B/F/TAF
B/F/TAF is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase while providing long-acting nucleotide protection.
B/F/TAF is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase while providing long-acting nucleotide protection. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection as a switch regimen in virologically suppressed patients.
At a glance
| Generic name | Switch to B/F/TAF |
|---|---|
| Also known as | Biktarvy |
| Sponsor | University of Nairobi |
| Drug class | Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
The combination contains bictegravir (integrase strand transfer inhibitor), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor). Together, these agents target multiple steps of HIV replication: bictegravir prevents integration of viral DNA into the host genome, while emtricitabine and tenofovir alafenamide inhibit reverse transcription of viral RNA into DNA.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection as a switch regimen in virologically suppressed patients
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Elevated creatinine
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV (PHASE2)
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (PHASE2, PHASE3)
- Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated (PHASE2, PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (PHASE3)
- B/F/TAF to DTG/3TC Switch Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Switch to B/F/TAF CI brief — competitive landscape report
- Switch to B/F/TAF updates RSS · CI watch RSS
- University of Nairobi portfolio CI